

# The QBRC neoantigen calling pipeline

 Tao Wang

Updated date: Nov 29, 2021



An abbreviated version of this protocol was published in Science Immunology in Feb 2020

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

DOI: 10.1126/sciimmunol.aaz3199

## Detailed protocol

Hello!

Thanks for your interest! Please refer to:

<https://github.com/tianshilu/QBRC-Somatic-Pipeline>

<https://github.com/tianshilu/QBRC-Neoantigen-Pipeline>

And let me know if you have any question. You can reach me via [tao.wang@utsw.edu](mailto:tao.wang@utsw.edu)

Thanks!

Tao

**How to cite:** (Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used)

1. Wang, T. (2021). The QBRC neoantigen calling pipeline. Bio-protocol Preprint. [bio-protocol.org/prep1455](https://bio-protocol.org/prep1455).
2. Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L., Xie, Z., Chen, M., Luke, J. J., Brugarolas, J., Hannan, R. and Wang, T. (2020). Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes . Science Immunology 5(44). DOI: [10.1126/sciimmunol.aaz3199](https://doi.org/10.1126/sciimmunol.aaz3199)

**Copyright:** Content may be subjected to copyright.